
At a glance:
Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and inflammation.
The findings can inform precision-targeted treatments for intestinal inflammation and disorders of gut motility.
The results add to a growing body of research showing the nervous and immune systems interact in various organs, including the brain, lungs, and skin.
After every meal, the intestines perform an action called peristalsis — moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.
For more than a century, scientists have known that nerve cells in the gut propel the colon to move, allowing the organ to perform its life-sustaining function. But exactly how these intestinal nerve cells do their job has remained elusive.
Now a new NIH-funded study led by researchers at Harvard Medical School and the Icahn School of Medicine at Mount Sinai has identified the mechanism behind this phenomenon, showing that the gut’s motility is altered by exercise, pressure, and inflammation.
The study results, based on experiments in mice and published March 24 in Cell, reveal that a pressure-sensing protein called PIEZO1 — named after the Greek word for pressure and the discovery of which won the 2021 Nobel Prize in Physiology or Medicine — plays a key role both in coordinating intestinal movements and keeping inflammation in this organ at bay.
If replicated in humans, the researchers said, the findings could inform the design of precision-targeted treatments that tame intestinal inflammation and treat disorders of gut motility, such as diarrhea and constipation.
“Eventually, we might stimulate PIEZO1 to speed up excretion, block it to treat diarrhea, or use it as a novel target to treat intestinal inflammation in IBD patients,” said Ruaidhrí Jackson, assistant professor of immunology in the Blavatnik Institute at HMS and co-senior author on the study with Hongzhen Hu from the Icahn School of Medicine.
Authorship, funding, disclosures
Additional authors on the study include Zili Xie, Lillian Rose, Jing Feng, Yonghui Zhao, Yisi Lu, Harry Kane, Timothy J. Hibberd, Xueming Hu, Zhen Wang, Kaikai Zang, Xingliang Yang, Quentin Richardson, Rahmeh Othman, Olivia Venezia, Ademi Zhakyp, Fang Gao, Nobuya Abe, Keren Vigeland, Hongshen Wang, Camren Branch, Coco Duizer, Liwen Deng, Xia Meng, Lydia Zamidar, Max Hauptschein, Ronan Bergin, Xinzhong Dong, Issac Chiu, Brian S. Kim, and Nick Spencer.
The work was supported by the NIH Directors New Innovators Program (DP2AI169979), the Paul Allen Distinguished Investigator Program, the Kenneth Rainin Innovator Award, the Crohn’s and Colitis of America Foundation Senior Research Award (959859), the National Science Foundation Graduate Research Fellowship Program (DGE2140743), and the Allen Discovery Center program, a Paul G. Allen Frontiers Group advised program of the Paul G. Allen Family Foundation.
Hu has served as a consultant for Formation Bio and Almirall on topics unrelated to this study, and his lab has received sponsored research from Triveni Bio. Kim is founder of KliRNA Biotech; he has served as a consultant for 23andMe, ABRAX Japan, AbbVie, Almirall, Amgen, Arcutis Biotherapeutics, Arena Pharmaceuticals, argenx, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Clexio Biosciences, Eli Lilly and Company, Escient Pharmaceuticals, Evommune, Galderma, Genentech, GlaxoSmithKline, Granular Therapeutics, Incyte Corporation, Innovaderm Research, Janssen, Kiniksa, LEO Pharma, Maruho, Novartis, Pfizer, Recens Medical, Regeneron Pharmaceuticals, Sanofi, Septerna, Triveni Bio, Vial, and WebMD; he has stock in ABRAX Japan, KliRNA Biotech, Locus Biosciences, and Recens Medical; he holds a patent for the use of JAK1 inhibitors for chronic pruritus; and he has a patent pending for the use of JAK inhibitors for interstitial cystitis.